No evidence of difference in mortality with amoxicillin versus co-amoxiclav for hospital treatment of community-acquired pneumonia by Wei, J, Uppal, A, Nganjimi, C, Warr, H, Ibrahim, Y, Gu, Q, Yuan, H, Rahman, N, Jones, N, Walker, S, Eyre, D

“…We aim to compare outcomes in CAP patients treated with amoxicillin (narrowspectrum) versus co-amoxiclav (broad-spectrum), to understand if narrow-spectrum antibiotics could be used more widely.…”